The institute recommended that existing GLP-1 makers, and those with products in the pipeline, should consider steep discounts to prices in exchange for higher volume. What has to happen is we have to move from a low-volume, high-price business model, to a high-volume, low-price business model, Nunn said
For additional insight into these strategic challenges, see Pharma Marketing Network featured articles
Please note that deals can expire, and all prices are subject to change.
Real-world data for retatrutide do not yet exist because the drug is not approved
While GLP-1s can reduce appetite and cravings, pairing treatment with supportive lifestyle habits and following nutrition tips from your clinician often makes changes feel more noticeable and sustainable
Second, head-to-head comparative trials between GLP-1 RA monotherapy, dual agonists, and triple agonists in MASH populations with histological endpoints are entirely lacking: current selection among agents relies on indirect comparisons across trials with different inclusion criteria and follow-up periods
